Anti-proliferative and cytoskeleton-disruptive effects of icariin on HepG2 cells

Wang,Zhi‑Min; Song,Nan; Ren,Yan‑Ling

doi:10.3892/mmr.2015.4282

Anti-proliferative and cytoskeleton-disruptive effects of icariin on HepG2 cells

Authors:
- Zhi‑Min Wang
- Nan Song
- Yan‑Ling Ren
View Affiliations

Affiliations: The First Clinical Institute, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning 110847, P.R. China, Key Laboratory of Ministry of Education for Traditional Chinese Medicine Viscera-State Theory and Applications, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning 110847, P.R. China , School of Chinese Medical Formulae, College of Basic Medicine, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning 110847, P.R. China
Published online on: September 2, 2015 https://doi.org/10.3892/mmr.2015.4282
Pages: 6815-6820

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Several biological properties of icariin have been identified, including its anticancer effect. However, the potential mechanisms underlying the effect of icariin on HepG2 hepatocellular carcinoma cells remain to be elucidated. The aim of the present study was to examine the effects of icariin on the proliferation and cytoskeleton of HepG2 cells. A 3‑(4,5‑dimethylthiazol‑2‑yl)‑2,5 diphenyltetrazolium bromide assay was used to assess the antiproliferative effects of icariin and to determine the optimal concentration and treatment schedule of icariin on the HepG2 cells. Cell cycle analysis was performed using fluorescence activated cell sorting, the protein expression of B‑cell lymphoma (Bcl)‑2 was determined using immunohistochemical and western blot analyses, and F‑actin in the cells was examined using confocal microscopy. The chemotherapeutic drug, oxaliplatin, was used as a positive control. The results demonstrated that the optimal concentration of icarrin to produce an antiproliferative effect on HepG2 cells was 10‑5 mol/l, and the optimal treatment duration was 72 h. The icariin group had a significantly higher proportion of cells in the G0/G1 phase, compared with the control group, treated with high glucose Dulbecco's modified Eagles medium with 10% fetal bovine serum (P<0.05). The proportion of HepG2 cells in the S phase was significantly lower in the oxaliplatin (24.19%; P<0.05) and icariin (21.07%; P<0.01) groups, compared with the control group (28.62%). Icariin markedly decreased the expression of Bcl‑2, compared with the control (P<0.01), and disrupted the polymerization of F‑actin filaments in the HepG2 cells. Therefore, the present study demonstrated that, at an optimum concentration of 10‑5 mol/l, icariin inhibited the proliferation of the HepG2 cells, promoted apoptosis by decreasing the expression of Bcl‑2, and disrupted the actin cytoskeleton.

View Figures

View References

1	Adams JM and Cory S: The Bcl-2 protein family: Arbiters of cell survival. Science. 281:1322–1326. 1998. View Article : Google Scholar : PubMed/NCBI
2	Bell RM: A review of complementary and alternative medicine practices among cancer survivors. Clin J Oncol Nurs. 14:365–370. 2010. View Article : Google Scholar : PubMed/NCBI
3	Chang HC, Chen TL and Chen RM: Cytoskeleton inter-ruption in human hepatoma HepG2 cells induced by ketamine occurs possibly through suppression of calcium mobilization and mitochondrial function. Drug Metab Dispos. 37:24–31. 2009. View Article : Google Scholar
4	Colombo E, Marine J-C, Danovi D, Falini B and Pelicci PG: Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol. 4:529–533. 2002. View Article : Google Scholar : PubMed/NCBI
5	Hall A: Rho GTPases and the actin cytoskeleton. Science. 279:509–514. 1998. View Article : Google Scholar : PubMed/NCBI
6	He W, Sun H, Yang B, Zhang D and Kabelitz D: Immunoregulatory effects of the herba Epimediia glycoside icariin. Arzneimittelforschung. 45:910–913. 1995.PubMed/NCBI
7	Huo X, Xu XJ, Chen YW, Yang HW and Piao ZX: Filamentous-actins in human hepatocarcinoma cells with CLSM. World J Gastroenterol. 10:1666–1668. 2004. View Article : Google Scholar : PubMed/NCBI
8	Kluck RM, Bossy-Wetzel E, Green DR and Newmeyer DD: The release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis. Science. 275:1132–1136. 1997. View Article : Google Scholar : PubMed/NCBI
9	Lau WY and Lai EC: Hepatocellular carcinoma: Current management and recent advances. Hepatobiliary Pancreat Dis Int. 7:237–257. 2008.PubMed/NCBI
10	Liu WJ, Xin ZC, Xin H, Yuan YM, Tian L and Guo YL: Effects of icariin on erectile function and expression of nitric oxide synthase isoforms in castrated rats. Asian J Androl. 7:381–388. 2005. View Article : Google Scholar : PubMed/NCBI
11	Fiume L, Manerba M, Vettraino M and Di Stefano G: Effect of sorafenib on the energy metabolism of hepatocellular carcinoma cells. Eur J Pharmacol. 670:39–43. 2011. View Article : Google Scholar : PubMed/NCBI
12	Okuda K: Hepatocellular carcinoma: Recent progress. Hepatology. 15:948–963. 1992. View Article : Google Scholar : PubMed/NCBI
13	Shi MD, Liao YC, Shih YW and Tsai LY: Nobiletin attenuates metastasis via both ERK and PI3K/Akt pathways in HGF-treated liver cancer HepG2 cells. Phytomedicine. 20:743–752. 2013. View Article : Google Scholar : PubMed/NCBI
14	Shumilina EV, Negulyaev YA, Morachevskaya EA, Hinssen H and Khaitlina SY: Regulation of sodium channel activity by capping of actin filaments. Mol Biol Cell. 14:1709–1716. 2003. View Article : Google Scholar : PubMed/NCBI
15	Sun L, Chen W, Qu L, Wu J and Si J: Icaritin reverses multidrug resistance of HepG2/ADR human hepatoma cells via downregulation of MDR1 and P-glycoprotein expression. Mol Med Rep. 8:1883–1887. 2013.PubMed/NCBI
16	Tong JS, Zhang QH, Huang X, et al: Icaritin causes sustained ERK1/2 activation and induces apoptosis in human endometrial cancer cells. PLoS One. 6:e167812011. View Article : Google Scholar : PubMed/NCBI
17	Zhang XH, Zou ZQ, Xu CW, Shen YZ and Li D: Myricetin induces G2/M phase arrest in HepG2 cells by inhibiting the activity of the cyclin B/Cdc2 complex. Mol Med Rep. 4:273–277. 2011.PubMed/NCBI
18	Tan W, Lu J, Huang M, Li Y, Chen M, Wu G, Gong J, Zhong Z, Xu Z, Dang Y, et al: Anti-cancer natural products isolated from chinese medicinal herbs. Chin Med. 6:272011. View Article : Google Scholar : PubMed/NCBI
19	Wang QQ, Zhang ZY, Xiao JY, Yi C, Li LZ, Huang Y and Yun JP: Knockdown of nucleophosmin induces S-phase arrest in HepG2 cells. Chin J Cancer. 30:853–860. 2011. View Article : Google Scholar : PubMed/NCBI
20	Wang Y, Dong H, Zhu M, Ou Y, Zhang J, Luo H, Luo R, Wu J, Mao M, Liu X, et al: Icariin exterts negative effects on human gastric cancer cell invasion and migration by vasodilator-stimulated phosphoprotein via Rac1 pathway. Eur J Pharmacol. 635:40–48. 2010. View Article : Google Scholar : PubMed/NCBI
21	Hu W and Kavanagh JJ: Anticancer therapy targeting the apoptotic pathway. Lancet Oncol. 4:721–729. 2008. View Article : Google Scholar
22	Williams JI, Weitman S, Gonzalez CM, Jundt CH, Marty J, Stringer SD, Holroyd KJ, Mclane MP, Chen Q, Zasloff M and Von Hoff DD: Squalamine treatment of human tumors in nu/nu mice enhances platinum-based chemotherapies. Clin Cancer Res. 7:724–733. 2001.PubMed/NCBI
23	Skillman KM, Diraviyam K, Khan A, et al: Evolutionarily divergent, unstable filamentous actin is essential for gliding motility in apicomplexan parasites. PLoS Pathog. 7:e10022802011. View Article : Google Scholar : PubMed/NCBI
24	Ozyamak E, Kollman JM and Komeili A: Bacterial actins and their diversity. Biochemistry. 52:6928–6939. 2015. View Article : Google Scholar :
25	Xu HB and Huang ZQ: Icariin enhances endothelial nitric-oxide synthase expression on human endothelial cells in vitro. Vascul Pharmacol. 47:18–24. 2007. View Article : Google Scholar : PubMed/NCBI
26	Yan MX, Yang J, Sun Q, Liu CH, Wang YG and Wang WQ: Hepatocellular carcinoma that arose from primary Sjögren's syndrome. Ann Hepatol. 12:824–829. 2013.PubMed/NCBI
27	Yang JX, Fichtner I, Becker M, Lemm M and Wang XM: Anti-proliferative efficacy of icariin on HepG2 hepatoma and its possible mechanism of action. Am J Chin Med. 37:1153–1165. 2009. View Article : Google Scholar : PubMed/NCBI
28	Yang YL: Polymerization of actins. Biology (Basel). 18:13–14. 1995.
29	Zhang DW, Cheng Y, Wang NL, Zhang JC, Yang MS and Yao XS: Effects of total flavonoids and flavonol glycosides from Epimedium koreanum Nakai on the proliferation and differentiation of primary osteoblasts. Phytomedicine. 15:55–61. 2008. View Article : Google Scholar